Foghorn Therapeutics Inc. (FHTX) stock
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/300% above fair value
$2.05−0.04 (-1.91%)
Close on Nov 12, 2026Market cap $121.74MP/E 29.3Yield –
Foghorn Therapeutics cash
Cash and short-term investments held at the end of each period.
Foghorn Therapeutics's cash was $80.30M at Sep 30, 2026. For fiscal 2025 it was $80.88M, up 41.5% from the year before. The highest annual figure on record is $102.87M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.88M | +41.5% |
| FY2024 | Dec 31, 2024 | $57.16M | -30.3% |
| FY2023 | Dec 31, 2023 | $82.04M | +52.2% |
| FY2022 | Dec 31, 2022 | $53.92M | -47.6% |
| FY2021 | Dec 31, 2021 | $102.87M | +8.8% |
| FY2020 | Dec 31, 2020 | $94.53M | +447.8% |
| FY2019 | Dec 31, 2019 | $17.26M | -57.5% |
| FY2018 | Dec 31, 2018 | $40.59M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $80.30M | -10.1% |
| Q2 FY2026 | Jun 30, 2026 | $68.08M | -6.2% |
| Q1 FY2026 | Mar 31, 2026 | $87.66M | +43.6% |
| Q4 FY2025 | Dec 31, 2025 | $80.88M | +41.5% |
| Q3 FY2025 | Sep 30, 2025 | $89.33M | +54.9% |
| Q2 FY2025 | Jun 30, 2025 | $72.57M | -47.8% |
| Q1 FY2025 | Mar 31, 2025 | $61.03M | -23.0% |
| Q4 FY2024 | Dec 31, 2024 | $57.16M | -30.3% |
| Q3 FY2024 | Sep 30, 2024 | $57.68M | -18.0% |
| Q2 FY2024 | Jun 30, 2024 | $138.95M | +140.8% |
| Q1 FY2024 | Mar 31, 2024 | $79.25M | +56.5% |
| Q4 FY2023 | Dec 31, 2023 | $82.04M | +52.2% |
| Q3 FY2023 | Sep 30, 2023 | $70.31M | -19.7% |
| Q2 FY2023 | Jun 30, 2023 | $57.70M | -5.7% |
| Q1 FY2023 | Mar 31, 2023 | $50.64M | -76.3% |
| Q4 FY2022 | Dec 31, 2022 | $53.92M | -47.6% |
| Q3 FY2022 | Sep 30, 2022 | $87.60M | +51.5% |
| Q2 FY2022 | Jun 30, 2022 | $61.21M | -51.1% |
| Q1 FY2022 | Mar 31, 2022 | $213.65M | +221.5% |
| Q4 FY2021 | Dec 31, 2021 | $102.87M | +8.8% |
| Q3 FY2021 | Sep 30, 2021 | $57.84M | -22.5% |
| Q2 FY2021 | Jun 30, 2021 | $125.17M | +242.3% |
| Q1 FY2021 | Mar 31, 2021 | $66.45M | +1830.0% |
| Q4 FY2020 | Dec 31, 2020 | $94.53M | +447.8% |
| Q3 FY2020 | Sep 30, 2020 | $74.62M | +247.1% |
| Q2 FY2020 | Jun 30, 2020 | $36.56M | -9.9% |
| Q1 FY2020 | Mar 31, 2020 | $3.44M | – |
| Q4 FY2019 | Dec 31, 2019 | $17.26M | – |
| Q3 FY2019 | Sep 30, 2019 | $21.50M | – |
| Q4 FY2018 | Dec 31, 2018 | $40.59M | – |
See a number that looks wrong?